VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
PRICE: 0 CENTS
ChemoMetec A/S
CHEMM · Nasdaq Copenhagen A/S
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
ChemoMetec A/S is a Danish life-science tools company listed on Nasdaq Copenhagen, focused on cell-counting instruments, consumables, software and service. H1 2025/26 revenue was about 95% LCB workflows in life-science research, cell and gene therapy, and bioprocessing, with a small production-QC niche in animal semen, beer and milk. The core moat rests on proprietary consumables around the NucleoCounter installed base, customer validation and qualification friction in regulated workflows, and an emerging automation/software integration layer through XcytoMatic and XM Octopus. Counter-pressures are real: North American demand slowed, automation validations are taking longer than expected, XcytoMatic can dilute cassette economics, and larger life-science equipment vendors can bundle broader automation suites.
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Market structure
Oligopoly
Market share
15%-25% (estimated)
HHI: —
Coverage
2 segments · 5 tags
Updated 2026-04-24
Segments
Life science research, cell and gene therapy, and bioprocessing
Global cell counting and analysis instruments for LCB workflows
Revenue
94.8%
Structure
Oligopoly
Pricing
moderate
Share
15%-25% (estimated)
Peers
Production control and quality control of animal semen, beer and milk
Livestock semen, beer and milk cell-counting quality-control instruments
Revenue
5.2%
Structure
Quasi-Monopoly
Pricing
moderate
Share
30%-65% (implied)
Peers
Moat Claims
Life science research, cell and gene therapy, and bioprocessing
Global cell counting and analysis instruments for LCB workflows
H1 2025/26 revenue share uses DKK236.0m LCB revenue over DKK249.0m total; no business-area EBIT is reported because the group identifies one IFRS operating segment.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
NucleoCounter placements pull through cassettes, chambers, reagents, test kits and service; consumables/services were 68% of H1 2025/26 revenue, though XcytoMatic uses less plastic.
Erosion risks
- Reusable XcytoMatic cuvettes may lower cassette pull-through versus NucleoCounter systems.
- US customer budget delays can defer installed-base expansion.
- Large competitors can bundle instruments with broader lab-automation platforms.
Leading indicators
- Consumables revenue growth versus instrument revenue growth
- Installed NucleoCounter and NC-203 base growth
- Service and reagent attach rates on XcytoMatic systems
Counterarguments
- Automation may favor reusable cuvettes and integrated platforms over disposable cassette economics.
- Large life-science tools vendors can discount instruments to win installed base.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Cell/gene-therapy and bioprocessing workflows require validation, data control and health-authority approval, making supplier changes slow after design-in.
Erosion risks
- The same validation friction that protects the installed base can delay new revenue conversion.
- Incumbent competitors may already be validated inside customer workflows.
- Manufacturing-process changes can reduce the need for standalone cell-counting steps.
Leading indicators
- Number of customer validations in cell and gene therapy and bioprocessing
- Conversion rate from validation projects to multi-instrument deployments
- Repeat XM30, XM40 and XM50 orders after qualification
Counterarguments
- Qualification friction can protect incumbent competitors as much as ChemoMetec.
- Big pharma customers may prefer broader automation-suite vendors with more validated modules.
Interoperability Hub
Network
Interoperability Hub
Strength
Durability
Confidence
Evidence
XM Octopus and the Roche LOI could turn ChemoMetec into an automation node in bioprocess monitoring, but proof is early.
Erosion risks
- The Roche letter of intent may not lead to validated commercial products.
- Partners could control the software layer and customer relationship.
- Open APIs may lower proprietary lock-in.
Leading indicators
- XM Octopus pilot and soft-launch progress
- Roche connectivity milestones
- Share of XcytoMatic orders with software or API modules
Counterarguments
- Integration standards can commoditize point instruments.
- Roche and other suite vendors may capture the higher-value workflow layer.
Production control and quality control of animal semen, beer and milk
Livestock semen, beer and milk cell-counting quality-control instruments
H1 2025/26 revenue share uses DKK13.0m production-QC revenue over DKK249.0m total; business-area allocation is partly based on allocation keys.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
SP-100 has long-lived trust in livestock sperm cell counting; the two-decade-old product is still considered up to date by customers.
Erosion risks
- The small non-core segment may receive limited R&D priority.
- Modern AI semen analyzers could leapfrog the SP-100 platform.
- Livestock artificial-insemination station consolidation could increase buyer power.
Leading indicators
- Production-QC revenue stability
- SP-100 replacement and retention trends
- Customer retention at bull, boar and stallion stations
Counterarguments
- A 20-year-old product may be vulnerable to new imaging and software alternatives.
- Small segment scale limits reinvestment relative to larger life-science tools vendors.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Production-QC has recurring consumables: H1 2025/26 business-area data shows DKK11.5m consumables against DKK1.2m instruments.
Erosion risks
- Installed SP-100 base could age out without a refreshed platform.
- Beer and milk applications are not priority growth areas.
- Weak instrument sales can eventually reduce consumables demand.
Leading indicators
- Production-QC consumables share of segment revenue
- Active installed SP-100 base
- Replacement instrument sales
Counterarguments
- The recurring consumables base is small and may decline if customers switch platforms.
- Consumables economics depend on aging hardware in a niche market.
Evidence
Consumables accounted for 45% of total revenue in the first half
Shows recurring consumables are a large part of the current revenue mix.
Our disposable cassette for the NucleoCounter instruments is key to our success within cell counting.
Directly supports proprietary consumables tied to installed instruments.
ChemoMetec's analytical equipment is typically used in areas subject to strict internal and external compliance requirements
Regulated workflow use supports customer qualification and switching friction.
An automation project typically takes three to five years
Long implementation cycles make vendor replacement slow once embedded.
validations, decisions, etc. are taking longer than expected.
Recent evidence that validation friction is economically material.
Showing 5 of 14 sources.
Risks & Indicators
Erosion risks
- Reusable XcytoMatic cuvettes may lower cassette pull-through versus NucleoCounter systems.
- US customer budget delays can defer installed-base expansion.
- Large competitors can bundle instruments with broader lab-automation platforms.
- The same validation friction that protects the installed base can delay new revenue conversion.
- Incumbent competitors may already be validated inside customer workflows.
- Manufacturing-process changes can reduce the need for standalone cell-counting steps.
Leading indicators
- Consumables revenue growth versus instrument revenue growth
- Installed NucleoCounter and NC-203 base growth
- Service and reagent attach rates on XcytoMatic systems
- Number of customer validations in cell and gene therapy and bioprocessing
- Conversion rate from validation projects to multi-instrument deployments
- Repeat XM30, XM40 and XM50 orders after qualification
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.